News

Details

Published: 09 June 2020

• portfolio-news

The US Food and Drug Administration has granted Breakthrough Device Designation for GTX Medical‘s implantable Go-2 system which was designed to promote the recovery of leg motor functions and neurological control in adults with spinal cord injuries (SCI) and paralysis. The Go-2 System provides Targeted Epidural Spinal Stimulation (TESS) therapy, promoting the recovery of leg motor functions and neurological control. The Company anticipates the first clinical trial for the complete Go-2 system in humans to take place in 2021. 

Details

Published: 04 June 2020

• portfolio-news

Confo Therapeutics today announced the appointment of Paolo Vicini in the newly-created position of CDO effective June 1, 2020.With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini will apply his experience in translational and clinical sciences to support the Company as it moves its GPCR modulating small molecules through preclinical studies and into the clinic.

Details

Published: 26 May 2020

• portfolio-news

Themis and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.